1989 Fiscal Year Final Research Report Summary
STUDY OF TRANSFORMING GROWTH FACTOR IN HUMAN OSTEOSARCOMA
| Project/Area Number |
63480337
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | TEIKYO UNIVERSITY (1989)
The University of Tokyo (1988) |
|---|
Principal Investigator |
HIGAKI Shozo TEIKYO UNIVERSITY, ORTHOPEDIC SURGERY, ASSOCIATE PROFESSOR, 医学部, 助教授 (20107676)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
CHO Shogen TEIKYO UNIVERSITY, ORTHOPEDIC SURGERY, PROFESSOR, 医学部, 教授 (90082106)
|
|---|
| Project Period (FY) |
1988 – 1989
|
| Keywords | TRANSFORMING GROWTH FACTOR (TGF) / TGF activity / Osteosarcoma / Somatomedin / TGF-B / Prognosis |
|---|
| Research Abstract |
The purpose of present studies were performed to clarify what kinds of transforming growth factor (TGF) concerned in human osteosarcoma, and also to clarify whether TGF assay was useful for evaluating prognosis of osteosarcoma patients.
Eighteen osteosarcoma tissues were extracted according Roberts were studied what kinds of TGFs were existing and also studied correlations between TGF activity and clinical course of these patients.
Doses of Epidermal Growth Factor (EGF) and somatomedins was assayed by RIA assay, and TGF-alpha was assayed by EGF receptor competition assay, TGF activity was assayed by soft agar colony formation activity using NRK cells with or without EGF.
RESULTS: Neither EGF nor TGF-alpha was not detected in any crude TGFs of osteosarcoma, and significant somatomedins levels were detected in every cases, and every crude TGFs were enhanced with EGF and some crude TGFs inhibited growth of porcine endothelial cells, significant doses of TGF betal should be existing in osteosarcoma.
Correlations between TGF activity and AlP-ase were not observed (r=0.44). Significant correlations were observed between TGF activity and numbers of mitotic cells (r=0.77).
TGF activity was useful to predict prognosis. Although, all cases of high TGF activity above 120 units were dead within two years, only two cases out of nine of low TGF activity below 120 units were dead within two years (p<0.01). Although all of highly enhanced cases with EGF, were dead within three years, only three cases out of nine of enhanced cases low with EGF, were dead within three years (p<0.01). These results suggested that TGF assay was useful for predicting prognosis of osteosarcoma. TGFs of osteosarcoma were mainly TGF-beta and somatomedins.
|
